Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Hypomethylating agents for the treatment of myelodysplastic syndromes

    ... 5-azacytidine (azacitidine) and 5-deoxyazacytidine ( decitabine ). Clinical trials of hypomethylating agents in MDS still raise a ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Myelodysplastic syndromes.

    ... years. Lenalidomide , azacitidine , and decitabine are all FDA-approved agents to treat MDS; however, the only ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

    ... approved in the United States-- azacitidine or decitabine --to patients with aggressive forms of myelodysplastic ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Pharmacotherapy of myelodysplastic syndromes.

    ... to the hypomethylating agents azacitidine and decitabine in non-del(5q) MDS patients remains at approximately 50%, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.

    ... ( azacitidine ) and 5-aza-2-deoxycytidine ( decitabine ), are both effective in high-risk MDS, but about 50% of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Current and future management options for myelodysplastic syndromes.

    ... such as lenalidomide , azacitidine and decitabine . Prior to these developments, supportive care measures ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

    ... include hypomethylating agents ( azacitidine and decitabine ), intensive chemotherapy (ICT), and allogeneic stem-cell ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Myelodysplastic syndromes in older adults.

    ... Developments using the drugs lenalidomide , decitabine , and azacitidine have offered treatment options to ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. How much? How frequent? How long? A clinical guide to new therapies in myelodysplastic syndromes.

    ... for treatment of MDS: (1) azacitidine , (2) decitabine , and (3) lenalidomide . Clinical results with each of ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease

    ... lenalidomide ), and hypomethylating therapy [HMT ( decitabine and 5-azacytidine)]. All patients will eventually lose their ...

    Research Article last updated 07/20/2018 - 5:15pm.